SuperworthPacific Biosciences of California profit margin PACB
Gross, operating and net profit as a share of revenue over the last twelve months, from 2015.
- Net margin, 12 months
- −82.5%
- Operating margin, 12 months
- −83.5%
- Peer median
- 13.6%
Over the twelve months to Jun 30, 2026, Pacific Biosciences of California kept −82.5% of its revenue as net profit, with an operating margin of −83.5% and a gross margin of 36.4%.
Five years earlier its net margin was −73.0%.
The median for 6 diagnostics and research stocks of a similar size is 13.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | n/a | n/a | 28.6% |
| FY2024 | n/a | n/a | 24.2% |
| FY2023 | n/a | n/a | 26.3% |
| FY2022 | n/a | n/a | 38.2% |
| FY2021 | n/a | n/a | 45.1% |
| FY2020 | 37.3% | n/a | 41.3% |
| FY2019 | −92.6% | n/a | 38.0% |
| FY2018 | n/a | n/a | 31.9% |
| FY2017 | −98.6% | −96.1% | 37.1% |
| FY2016 | −82.0% | −78.5% | 48.7% |
| FY2015 | −34.2% | −31.4% | 57.6% |
| FY2014 | n/a | n/a | 38.6% |
| FY2013 | n/a | n/a | 22.8% |
| FY2012 | n/a | n/a | 3.6% |
| FY2011 | n/a | n/a | 38.5% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −82.5% | n/a | −83.5% | |
| Q1 FY26 | −80.3% | n/a | −83.3% | |
| Q4 FY25 | n/a | n/a | n/a | |
| Q3 FY25 | n/a | n/a | n/a | |
| Q2 FY25 | n/a | n/a | n/a | |
| Q1 FY25 | n/a | n/a | n/a | |
| Q4 FY24 | n/a | n/a | n/a | |
| Q3 FY24 | n/a | n/a | n/a | |
| Q2 FY24 | n/a | n/a | n/a | |
| Q1 FY24 | n/a | n/a | n/a | |
| Q4 FY23 | n/a | n/a | n/a | |
| Q3 FY23 | n/a | n/a | n/a |
Against its peers
Companies in Medical - Diagnostics & Research nearest Pacific Biosciences of California's size, closest first, today.
| Company | Profit margin |
|---|---|
| PACBPacific Biosciences of California | −82.5% |
| NRCNRC Health | 4.2% |
| CDNACareDx | 24.2% |
| VCYTVeracyte | 20.4% |
| ICCCImmucell | 2.6% |
| BLLNBillionToOne | 9.5% |
| LNTHLantheus | 17.7% |
| Peer median | 13.6% |
Where Pacific Biosciences of California ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Pacific Biosciences of California
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.